ArticleScientific reports2026
Detection of known gene fusions in cancer cell lines using whole-genome bisulfite sequencing data.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Whole-genome bisulfite sequencing (WGBS) provides multiple molecular information layers including methylation, copy number variations (CNVs), single nucleotide variants (SNVs), and fragmentome patterns in cell-free DNA (cfDNA) while gene fusion detection from WGBS data has not been widely explored. We applied a custom analysis pipeline using bisulfite-aware aligners supporting split read alignment to detect known gene fusions from WGBS data and validated this approach using cancer cell lines with characterized fusion events. Using K562 cells harboring the BCR-ABL1 fusion, WGBS-derived breakpoints showed concordance with WGS-derived coordinates. Serial dilution experiments with K562 DNA in NA12878 background at average 63X coverage established a limit of detection (LoD) of 8.1% fusion-positive DNA fraction, demonstrating 100% detection rate at ≥10%. Furthermore, our method with MCF-7 cells detected 10 of 12 validated fusions with high technical reproducibility (Pearson r > 0.99), including both inter-chromosomal and intra-chromosomal events. This approach confirms that known gene fusions can be reliably detected from WGBS data, particularly well-suited for applications where methylation and fusion profiling are both required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.